ProgenityLogo.jpg
Progenity Appoints Adi Mohanty as Chief Executive Officer
09 nov. 2021 06h30 HE | Progenity, Inc.
SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the appointment of Adi Mohanty as Chief Executive Officer of the...
ProgenityLogo.jpg
Progenity Announces Appointment of Jill Howe to its Board of Directors
04 nov. 2021 06h30 HE | Progenity, Inc.
SAN DIEGO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced the appointment of Jill Howe to its board of directors effective November...
ProgenityLogo.jpg
Progenity to Report Third Quarter 2021 Financial Results and Provide Corporate Update
03 nov. 2021 07h30 HE | Progenity, Inc.
SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), an innovative biotechnology company, today announced that it will report third quarter 2021 financial results on...
ProgenityLogo.jpg
Progenity Reduces Outstanding Debt by $20.175 Million Through a Private Exchange of $20.175 Million of Its 7.25% Convertible Senior Notes Due 2025 for Shares of Common Stock
26 oct. 2021 07h30 HE | Progenity, Inc.
SAN DIEGO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, today announced that it has entered into privately negotiated...
ProgenityLogo.jpg
Progenity to Participate in Crohn’s & Colitis Foundation’s Fourth Annual IBD Innovate Conference
19 oct. 2021 07h30 HE | Progenity, Inc.
SAN DIEGO, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today that the company will participate in the fourth annual IBD Innovate...
ProgenityLogo.jpg
Progenity Announces Several Patents Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Ingestible Therapeutics Technologies
13 oct. 2021 07h30 HE | Progenity, Inc.
SAN DIEGO, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today that the United States Patent and Trademark Office (USPTO) has...
ProgenityLogo.jpg
Progenity Announces Closing of $20 Million Registered Direct Offering of Common Stock Priced at Premium to Market Under Nasdaq Rules
06 oct. 2021 16h02 HE | Progenity, Inc.
SAN DIEGO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, today announced the closing of its previously announced registered...
ProgenityLogo.jpg
Progenity Announces $20 Million Registered Direct Offering of Common Stock Priced at Premium to Market Under Nasdaq Rules
04 oct. 2021 13h40 HE | Progenity, Inc.
SAN DIEGO, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, today announced that it has entered into a definitive agreement with...
ProgenityLogo.jpg
Progenity to Participate in 11th Annual Partnership Opportunities in Drug Delivery Conference
21 sept. 2021 07h30 HE | Progenity, Inc.
SAN DIEGO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today that the company will participate in the 11th annual Partnership...
22157.jpg
Global Cell Therapy Market Opportunity: USD 45 Billion+ By 2028
06 sept. 2021 04h23 HE | Research and Markets
Dublin, Sept. 06, 2021 (GLOBE NEWSWIRE) -- The "Global Cell Therapy Market Outlook, Patent & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering. In last...